BR9714004A - Novos vetores de expressão contendo genes de ligantes á moléculas acessórias e seu uso para imuno-modulação e tratamento de malignidades e doença auto-imune - Google Patents

Novos vetores de expressão contendo genes de ligantes á moléculas acessórias e seu uso para imuno-modulação e tratamento de malignidades e doença auto-imune

Info

Publication number
BR9714004A
BR9714004A BR9714004-0A BR9714004A BR9714004A BR 9714004 A BR9714004 A BR 9714004A BR 9714004 A BR9714004 A BR 9714004A BR 9714004 A BR9714004 A BR 9714004A
Authority
BR
Brazil
Prior art keywords
immunomodulation
treatment
malignancies
expression vectors
autoimmune disease
Prior art date
Application number
BR9714004-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas J Kipps
Sanjai Sharma
Mark Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9714004A publication Critical patent/BR9714004A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR9714004-0A 1996-12-09 1997-12-08 Novos vetores de expressão contendo genes de ligantes á moléculas acessórias e seu uso para imuno-modulação e tratamento de malignidades e doença auto-imune BR9714004A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PCT/US1997/022740 WO1998026061A2 (en) 1996-12-09 1997-12-08 Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease

Publications (1)

Publication Number Publication Date
BR9714004A true BR9714004A (pt) 2000-05-02

Family

ID=26708033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714004-0A BR9714004A (pt) 1996-12-09 1997-12-08 Novos vetores de expressão contendo genes de ligantes á moléculas acessórias e seu uso para imuno-modulação e tratamento de malignidades e doença auto-imune

Country Status (16)

Country Link
US (3) US7070771B1 (https=)
EP (4) EP2287309A1 (https=)
JP (1) JP4015201B2 (https=)
CN (1) CN1221662C (https=)
AT (2) ATE547524T1 (https=)
AU (1) AU5795798A (https=)
BR (1) BR9714004A (https=)
CA (2) CA2274498C (https=)
DE (1) DE69739220D1 (https=)
DK (1) DK0948614T3 (https=)
ES (1) ES2321246T3 (https=)
IL (3) IL130247A0 (https=)
NO (2) NO327411B1 (https=)
NZ (1) NZ336092A (https=)
PT (1) PT948614E (https=)
WO (1) WO1998026061A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20050214311A1 (en) * 2002-02-25 2005-09-29 Screaton Gavin R Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
BR112015008612A2 (pt) * 2012-10-17 2017-09-26 Vascular Biogenics Ltd métodos de tratamento utilizando adenovirus
CN106574241A (zh) * 2014-03-27 2017-04-19 密执安大学评议会 癌症免疫疗法组合物和方法
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
WO2018191369A1 (en) 2017-04-12 2018-10-18 Memgen, Llc Methods of cd40 and toll like receptor immune activation
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPH082315B2 (ja) 1987-05-29 1996-01-17 財団法人相模中央化学研究所 リンホトキシンを含む融合蛋白質
ATE148992T1 (de) 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
CZ283533B6 (cs) 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
ATE256180T1 (de) 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
EP0751781B1 (en) 1993-12-23 2004-05-26 Immunex Corporation Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders
JPH09508009A (ja) 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド
ES2251719T3 (es) 1994-04-28 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para la proliferacion y diferenciacion de celulas b y su empleo.
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
JPH09508140A (ja) 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
CA2304130C (en) 1997-09-17 2008-10-28 Mochida Pharmaceutical Co., Ltd. Novel fas ligand derivative
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
JP2001505782A (ja) 2001-05-08
EP2145958B1 (en) 2012-02-29
JP4015201B2 (ja) 2007-11-28
NO327411B1 (no) 2009-06-22
DE69739220D1 (de) 2009-03-05
CA2707726C (en) 2013-10-22
ES2321246T3 (es) 2009-06-03
WO1998026061A2 (en) 1998-06-18
IL130247A (en) 2008-03-20
NO992756D0 (no) 1999-06-07
AU5795798A (en) 1998-07-03
IL130247A0 (en) 2000-06-01
EP0948614B1 (en) 2009-01-14
ATE420956T1 (de) 2009-01-15
CA2707726A1 (en) 1998-06-18
DK0948614T3 (da) 2009-05-11
WO1998026061A3 (en) 1998-11-19
EP1806360A2 (en) 2007-07-11
NO992756L (no) 1999-08-09
NZ336092A (en) 2001-09-28
ATE547524T1 (de) 2012-03-15
EP0948614A2 (en) 1999-10-13
US7070771B1 (en) 2006-07-04
CA2274498C (en) 2010-06-29
US7906638B2 (en) 2011-03-15
CN1221662C (zh) 2005-10-05
NO331434B1 (no) 2011-12-27
EP2287309A1 (en) 2011-02-23
CN1246892A (zh) 2000-03-08
EP1806360A3 (en) 2007-12-12
CA2274498A1 (en) 1998-06-18
US20100267129A1 (en) 2010-10-21
NO20074906L (no) 1999-08-09
PT948614E (pt) 2009-04-20
US20060183199A1 (en) 2006-08-17
US7524944B2 (en) 2009-04-28
IL178306A0 (en) 2007-02-11
EP2145958A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
BR9714004A (pt) Novos vetores de expressão contendo genes de ligantes á moléculas acessórias e seu uso para imuno-modulação e tratamento de malignidades e doença auto-imune
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
IL190793A0 (en) A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
DE69904831D1 (de) Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DE69939553D1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
DE69841110D1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
DE68922808D1 (de) Monoklonale Antikörper gegen den Rezeptor des Epidermis-Wachstumsfaktors und diese enthaltende therapeutische Zubereitungen.
DE69739478D1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
WO2004110345A8 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE329030T1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
ATE481986T1 (de) Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
DE60019725D1 (de) Verwendung eines mit dem peptid "elagigiltv" assoziierten enterobakterien-proteins ompa zur behandlung von melanomen
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE362531T1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
DE60033540D1 (de) Verabreichung von gammaglobulinen zur behandlung von lymphomen
DE60134545D1 (de) Verwendungen von tgap7 zur modulation der aktivierung von leukozyten
Taghian et al. Radiobiological parameters of four glioblastoma compared to four other histological types of human tumor xenografts in nude mice

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.